Taro Pharmaceutical Industries Ltd. logo
Taro Pharmaceutical Industries Ltd. TARO

Annual report 2022
added 07-25-2022

report update icon

Taro Pharmaceutical Industries Ltd. Cash Flow 2011-2026 | TARO

Annual Cash Flow Taro Pharmaceutical Industries Ltd.

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-159 M 45.8 M 272 M 324 M 324 M 438 M 395 M - 358 M 249 M - 181 M

Depreciation & Amortization

25.9 M 23.7 M 21.4 M 18.6 M 16.5 M 14.8 M 14.8 M 15.8 M 16.6 M 17.8 M - 18.7 M

Accounts Payables

1.37 M 1.76 M 4.45 M 1.55 M 4.33 M 6.49 M 12.3 M 12.1 M 10.7 M 497 K 23 M 23.3 M

Accounts Receivables

247 M 214 M 235 M 238 M 206 M 204 M 239 M 222 M 139 M 120 M 111 M 121 M

Total Inventories

210 M 180 M 153 M 148 M 145 M 141 M 139 M 120 M 118 M 110 M 110 M 107 M

All numbers in USD currency

Quarterly Cash Flow Taro Pharmaceutical Industries Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 78.1 M - - - 24.4 M

Depreciation & Amortization

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 4.6 M - - - 4.71 M

Accounts Payables

- - - - - - - 1.76 M - - - 4.45 M - - - 1.55 M - - - 4.33 M - - - 6.49 M - - - 12.3 M - - - 12.1 M - - - 10.7 M - - - 497 K - - - 459 K 23.3 M - - -

Accounts Receivables

- - - - - - - 214 M - - - 235 M - - - 238 M - - - 206 M - - - 204 M - - - 239 M - - - 222 M - - - 139 M - - - 120 M - - - 111 M 121 M - - -

Total Inventories

- - - - - - - 180 M - - - 153 M - - - 148 M - - - 145 M - - - 141 M - - - 139 M - - - 120 M - - - 118 M - - - 110 M - - - 110 M 107 M - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Taro Pharmaceutical Industries Ltd., reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
MannKind Corporation MannKind Corporation
MNKD
$ 3.56 24.48 % $ 1.09 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 47.41 -16.36 % $ 7.47 B usaUSA
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 596.76 4.29 % $ 26.4 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BioNTech SE BioNTech SE
BNTX
- - $ 27.2 B germanyGermany
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
INmune Bio INmune Bio
INMB
$ 1.52 -1.3 % $ 37.6 M usaUSA
Exelixis Exelixis
EXEL
$ 48.7 9.64 % $ 13.2 B usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 21.48 -3.89 % $ 3.56 B usaUSA
Fortress Biotech Fortress Biotech
FBIO
- - $ 71.1 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 3.15 1.19 % $ 655 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
- - $ 5.51 M israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.17 3.2 % $ 3.08 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 55.08 5.15 % $ 4.95 B schweizSchweiz
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.7 3.66 % $ 452 M britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael